Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mayo and LipoScience in Collaboration

By Labmedica staff writers
Posted on 24 Aug 2005
A collaborative agreement between Mayo Clinic's Department of Laboratory Medicine and Pathology (Rochester, MN, USA) and LipoSciences (Raleigh, NC, USA) has been announced, whereby the Mayo Clinic will validate the clinical utility of the nuclear magnetic resonance (NMR) LipoProfile test of LipoSciences as a tool to measure cardiovascular risks.

As part of its assessment, Mayo researchers will determine the value of the NMR LipoProfile test independently and as part of its novel cardiovascular risk marker panel, a group of emerging risk factors used to aid doctors in the assessments of their patients' risks for developing cardiovascular disease or experiencing a cardiovascular event such as a stroke.

The NMR LipoProfile is a simple blood test used by doctors to directly measure the number of atherogenic low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) particles as well as protective high-density lipoprotein (HDL) particles. More...
Measuring the numbers of "bad” lipoprotein particles (LDL-P) has been found to provide a better indication of the risk of coronary heart disease than measuring the level of "bad” cholesterol.

"Mayo Clinic is widely recognized as a leader in assessing novel technologies that have the potential to significantly impact medical decisions and patient management,” explained Richard O. Brajer, president and chief executive officer at LipoScience, Inc. "We believe a preeminent institution such as Mayo Clinic will generate additional independent clinical data further confirming the clinical value of the NMR LipoProfile test.”




Related Links:
Mayo Medical Laboratories
LipoScience

New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.